TIDMFDBK
RNS Number : 8407C
Feedback PLC
13 October 2022
Feedback plc
Result of AGM & Proposed Share Consolidation
Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the
specialist medical imaging technology company, announces that at
the Annual General Meeting ("AGM") held today all resolutions were
duly passed.
The results of the poll (including proxy votes on the
resolutions) are included below.
Resolutions Votes For** % of votes Votes Against % of votes Votes Total votes
cast*** cast*** Withheld*** cast***
1) To receive and
adopt the
Company's annual
accounts for the
year ended 31
May 2022
together
with the
Directors'
report and the
Auditors' report
thereon 1,435,070,825 100.00 0 0.00 1,636,537 1,435,070,825
------------- ------------- -------------- -------------- -------------- ---------------
2) To receive and
approve the
report on
Directors'
remuneration for
the year ended
31 May
2022 666,547,017 57.85 485,714,290 42.15 83,017,483 1,152,261,307
------------- ------------- -------------- -------------- -------------- ---------------
3) To re-appoint
Price Bailey LLP
as Auditor of
the Company 1,300,785,111 100.00 0 0.00 1,636,537 1,300,785,111
------------- ------------- -------------- -------------- -------------- ---------------
4) To authorise
the Directors to
determine the
fees payable to
the Auditor 1,435,070,825 100.00 0 0.00 1,636,537 1,435,070,825
------------- ------------- -------------- -------------- -------------- ---------------
5) To elect Anesh
Patel as a
Director of the
Company 1,435,037,825 100.00 33,000 0.00 1,636,537 1,435,070,825
------------- ------------- -------------- -------------- -------------- ---------------
6) To elect
Annemijn
Eschauzier as a
Director of the
Company 1,435,037,825 100.00 33,000 0.00 1,636,537 1,435,070,825
------------- ------------- -------------- -------------- -------------- ---------------
7) To re-elect
Rory Shaw as a
Director of the
Company 949,356,535 100.00 0 0.00 487,350,827 949,356,535
------------- ------------- -------------- -------------- -------------- ---------------
Special Business
8) That the
Directors be and
are hereby
generally and
unconditionally
authorised to
allot
relevant
securities
pursuant to
section 551 of
the Companies
Act 2006 1,388,179,455 96.73 46,891,370 3.27 1,636,537 1,435,070,825
------------- ------------- -------------- -------------- -------------- ---------------
Special
Resolution
9) To
resolve
that the
Directors
be
empowered
to allot
equity
securities
for cash
and/or to
sell
equity
securities
held as
treasury
shares for
cash 1,388,596,455 96.76 46,474,370 3.24 1,636,537 1,435,070,825
------------- ------------- -------------- -------------- -------------- ---------------
10) That every
200 ordinary
shares of
GBP0.0025 each
in the capital
of the Company
are hereby
consolidated
into one
ordinary share
of GBP0.50 1,376,208,959 95.90 58,861,866 4.10 1,636,537 1,435,070,825
------------- ------------- -------------- -------------- -------------- ---------------
Special
resolution
11) That, the
Articles be
amended by the
insertion of a
new article 2.5 1,376,208,959 95.90 58,861,866 4.10 1,636,537 1,435,070,825
Notes:
* "Votes For" include votes giving the Chairman discretion.
** Percentages exclude "Votes Withheld".
*** "Votes Withheld" are not votes in law and do not count in
the number of votes counted for or against a resolution.
**** "Total votes cast" do not include withheld votes.
Share Consolidation
Following the approval of the Consolidation Resolution
(resolution 10 above), every 200 ordinary shares of GBP0.0025 each
(the "Existing Shares") that are in issue as at 6.00 p.m. today
will be consolidated into one new ordinary share of GBP0.50 each
(the "New Ordinary Shares"). Other than the change in nominal
value, the New Ordinary Shares arising on implementation of the
Share Consolidation will have the same rights as the Existing
Ordinary Shares, including voting and other rights.
The New Ordinary Shares arising from the Share Consolidation
will be admitted to trading on AIM from 8.00 a.m. on 14 October
2022 ("Admission") with ISIN number GB00BJN59X09 and SEDOL code
BJN59X0.
Total Voting Rights
Following Admission, the Company's issued share capital will
comprise 13,334,659 New Ordinary Shares with voting rights. This
figure of 13,334,659 New Ordinary Shares may be used by
shareholders in the Company as the denominator for the calculations
by which they will determine if they are required to notify their
interest in, or a change in their interest in, the share capital of
the Company under the Disclosure Rules and Transparency Rules of
the United Kingdom Financial Conduct Authority.
Save as defined herein, capitalised terms have the same meaning
as in the Company's notice of AGM which is available on the
Company's website.
-Ends-
Enquiries:
Feedback plc +44 (0) 20 3997 7634
Tom Oakley, CEO IR@fbk.com
Anesh Patel, CFO
Panmure Gordon (UK) Limited
(NOMAD and Broker)
Emma Earl/Freddy Crossley (Corporate
Finance)
Rupert Dearden (Corporate Broking) +44 (0)20 7886 2500
Walbrook PR Ltd; Tel: 020 7933 8780 or feedbackplc@walbrookpr.com
Paul McManus/Nick Rome 07980 541 893 or 07748 325 236
or 07884 664 686
About Feedback
Feedback plc helps clinical teams to make better decisions
faster for patients. We design products that enhance clinician
access to patient data and to their colleagues. Our unique approach
centres around individual patient episodes, into which we pull
relevant clinical data from hospital systems and around which we
build remote clinical teams for collaboration. As a result, we
produce a digital infrastructure that makes patient data available
to clinicians in multiple settings, in a format that enables them
to meaningfully interact with it, providing flexibility to
clinicians and free movement of patients between provider settings
- clinicians can practice from anywhere and patients can attend any
care provider for treatment.
Our products Bleepa and CareLocker work together to deliver
unparalleled value to our customers. Bleepa is our application
layer and sits on top of CareLocker as our data layer. Bleepa is a
clinician facing platform that displays clinical results from a
patient's CareLocker at a certified and regulated quality, that is
suitable for clinical use and enables dialogue on a
patient-by-patient basis with colleagues through a secure,
auditable chat interface that links back to the patient medical
record. The CareLocker data storage model is built around the
patient. Our vision is one where relevant clinical data is always
available to the patient as well as to any care setting that they
may attend - a federated data architecture with the patient as the
tenant.
The Company has a number of growth opportunities domestically
and internationally across a range of markets including the NHS,
the veterinary market and private healthcare providers and its
highly scalable Software as a Service ("SaaS")-based revenue model
is expected to provide increasing levels of visibility as the
Company grows its customer base.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGKZMMGFFZGZZM
(END) Dow Jones Newswires
October 13, 2022 09:55 ET (13:55 GMT)
Feedback (LSE:FDBK)
Historical Stock Chart
From Jul 2024 to Jul 2024
Feedback (LSE:FDBK)
Historical Stock Chart
From Jul 2023 to Jul 2024